These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 33047859)

  • 1. Safety, pharmacokinetics and pharmacodynamics of BI 655064 in phase 1 clinical trials in healthy Chinese and Japanese subjects.
    Tsuda Y; Grimaldi C; Huang F; Benediktus E; Yagi N; Padula SJ; Jang IJ; Steffgen J
    Br J Clin Pharmacol; 2021 Apr; 87(4):2000-2013. PubMed ID: 33047859
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Rising Doses of BI 655064, an Antagonistic Anti-CD40 Antibody, in Healthy Subjects: A Potential Novel Treatment for Autoimmune Diseases.
    Schwabe C; Rosenstock B; Doan T; Hamilton P; Dunbar PR; Eleftheraki AG; Joseph D; Hilbert J; Schoelch C; Padula SJ; Steffgen J
    J Clin Pharmacol; 2018 Dec; 58(12):1566-1577. PubMed ID: 30113724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and pharmacodynamics of the factor XIa-inhibiting antibody osocimab in healthy male East Asian volunteers: Results from two phase 1 studies.
    Dong Z; Hashizume K; Friedrichs F; Liu P; Tanaka T; Liao Y
    Pharmacol Res Perspect; 2024 Oct; 12(5):e70012. PubMed ID: 39308062
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety, pharmacokinetics and pharmacodynamics of single rising doses of BI 655064, an antagonistic anti-CD40 antibody in healthy subjects: a potential novel treatment for autoimmune diseases.
    Albach FN; Wagner F; Hüser A; Igel J; Joseph D; Hilbert J; Schoelch C; Padula SJ; Steffgen J
    Eur J Clin Pharmacol; 2018 Feb; 74(2):161-169. PubMed ID: 29127458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of Single Doses of BI 425809 in Healthy Chinese and Japanese Subjects: A Randomized Study.
    Tsuda Y; Ugai H; Wunderlich G; Shin JG
    Clin Ther; 2019 May; 41(5):961-971. PubMed ID: 31005336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
    Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
    Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety, Tolerability, Pharmacokinetics, and Immunogenicity of the Anti-IFNAR1 Monoclonal Antibody QX006N: A First-in-Human Single Ascending Dose Study in Healthy Chinese Volunteers.
    Li X; Li B; Wang M; Fang M; Lou J; Liu J; Chen H; Ding Y
    BioDrugs; 2024 Mar; 38(2):313-321. PubMed ID: 38148466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Atacicept in a Randomized Trial in Healthy Caucasian and Japanese Subjects.
    Willen D; Uhl W; Wolna P; Papasouliotis O; Yalkinoglu Ö
    Eur J Drug Metab Pharmacokinet; 2020 Feb; 45(1):27-40. PubMed ID: 31529406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Randomized, Placebo-Controlled, Double-Blind Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Repeated Doses of Mirogabalin in Healthy Asian Volunteers.
    Jansen M; Warrington S; Dishy V; Ohwada S; Johnson L; Brown K; Ishizuka H
    Clin Pharmacol Drug Dev; 2018 Aug; 7(6):661-669. PubMed ID: 29663714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP3652, a Reversible Fatty Acid Amide Hydrolase Inhibitor, in Healthy, Nonelderly, Japanese Men and Elderly, Japanese Men and Women: A Randomized, Double-blind, Placebo-controlled, Single and Multiple Oral Dose, Phase I Study.
    Takizawa M; Hatta T; Iitsuka H; Katashima M; Sato Y; Kuroishi K; Nagashima H
    Clin Ther; 2020 May; 42(5):906-923. PubMed ID: 32456804
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel CRTH2 Antagonist BI 1021958 at Single Oral Doses in Healthy Men and Multiple Oral Doses in Men and Women With Well-Controlled Asthma.
    Fowler A; Koenen R; Hilbert J; Blatchford J; Kappeler D; Benediktus E; Wood C; Gupta A
    J Clin Pharmacol; 2017 Nov; 57(11):1444-1453. PubMed ID: 28609567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple Rising Doses of Oral BI 425809, a GlyT1 Inhibitor, in Young and Elderly Healthy Volunteers: A Randomised, Double-Blind, Phase I Study Investigating Safety and Pharmacokinetics.
    Moschetti V; Schlecker C; Wind S; Goetz S; Schmitt H; Schultz A; Liesenfeld KH; Wunderlich G; Desch M
    Clin Drug Investig; 2018 Aug; 38(8):737-750. PubMed ID: 29846887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of the Pharmacokinetics and Safety of Spesolimab, a Humanised Anti-interleukin-36 Receptor Monoclonal Antibody, in Healthy Non-Japanese and Japanese Subjects: Results from Phase I Clinical Studies.
    Joseph D; Thoma C; Haeufel T; Li X
    Clin Pharmacokinet; 2022 Dec; 61(12):1771-1787. PubMed ID: 36451029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Alirocumab in Healthy Chinese Subjects: A Randomized, Double-Blind, Placebo-Controlled, Ascending Single-Dose Study.
    Li H; Wei Y; Yang Z; Zhang S; Xu X; Shuai M; Vitse O; Wu Y; Baccara-Dinet MT; Zhang Y; Li J
    Am J Cardiovasc Drugs; 2020 Oct; 20(5):489-503. PubMed ID: 32080823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics, safety and tolerability of Bencycloquidium bromide, a novel selective muscarinic M1/M3 receptor antagonist, after single and multiple intranasal doses in healthy chinese subjects: an open-label, single-center, first-in-human study.
    Sun L; Ding L; Wang Y; Zhou W; Yan Z; Sun W; Zhang H; Ou N; Chen X
    Drugs R D; 2012 Mar; 12(1):17-28. PubMed ID: 22339483
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics, Safety, and Tolerability of Cedirogant in Healthy Japanese and Chinese Adults.
    Mohamed MF; Qian Y; D'Cunha R; Hao S; Carcereri De Prati R; Levy GF; Hew K; Liu W
    Clin Pharmacol Drug Dev; 2024 Jul; 13(7):801-809. PubMed ID: 38410874
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics, Pharmacodynamics, and Tolerability of AZD5718, an Oral 5-Lipoxygenase-Activating Protein (FLAP) Inhibitor, in Healthy Japanese Male Subjects.
    Knöchel J; Nelander K; Heijer M; Lindstedt EL; Forsberg GB; Whatling C; Shimada H; Han DS; Gabrielsen A; Garkaviy P; Ericsson H
    Clin Drug Investig; 2021 Oct; 41(10):895-905. PubMed ID: 34546534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics, Pharmacodynamics, and Safety of Dulaglutide After Single or Multiple Doses in Chinese Healthy Subjects and Patients with T2DM: A Randomized, Placebo-Controlled, Phase I Study.
    Xu J; Zhang Y; Li Y; Zhao X; Zhou W; Loghin C; Tham LS; Cui X; Cui Y; Wang W
    Adv Ther; 2022 Jan; 39(1):488-503. PubMed ID: 34787823
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The safety, tolerability and pharmacokinetics of BI 409306, a novel and potent PDE9 inhibitor: Overview of three Phase I randomised trials in healthy volunteers.
    Moschetti V; Kim M; Sand M; Wunderlich G; Andersen G; Feifel U; Jang IJ; Timmer W; Rosenbrock H; Boland K
    Eur Neuropsychopharmacol; 2018 May; 28(5):643-655. PubMed ID: 29567399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose study.
    Schiopu E; Chatterjee S; Hsu V; Flor A; Cimbora D; Patra K; Yao W; Li J; Streicher K; McKeever K; White B; Katz E; Drappa J; Sweeny S; Herbst R
    Arthritis Res Ther; 2016 Jun; 18(1):131. PubMed ID: 27267753
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.